CTY insider trading
NasdaqGM HealthcareCITY THERAPEUTICS, INC.: insider trade history from SEC Form 4 filings.
About CITY THERAPEUTICS, INC.
City Therapeutics, Inc. operates as a biopharmaceutical company focused on developing RNA interference (RNAi)-based medicines by engineering RNAi trigger molecules. The company develops RNAi-based medicines using engineered small interfering RNAs (siRNAs) and is building a pipeline of therapeutics targeting diseases across multiple therapeutic areas, including ophthalmologic conditions such as retinal diseases and geographic atrophy. It designs and engineers RNAi trigger molecules, such as smaller size, novel cleavage mechanisms, and tailored targeting ligands to enhance potency, specificity, and delivery to various tissue types. Its products includes CITY-FXI, is a city-engineered n-acetylgalactosamine -conjugated small interfering RNA therapeutic targeting factor XI; CITY-RBP4, is a city-engineered GalNAc-conjugated siRNA therapeutic, in development for the treatment of Stargardt disease; CITY-TFR2, is a city-engineered GalNAc-conjugated siRNA therapeutic candidate in development for anemia of chronic disease; The company advances these therapeutics from research through clinical and commercial development stages and engages in strategic collaborations to co-develop RNAi clinical candidates. It has a strategic collaborations with Bausch + Lomb Ireland Limited and Biogen MA Inc. to advance extrahepatic RNAi therapeutics for diseases of the eye and the central nervous system. The company serves clients in the pharmaceutical, biotechnology, and life sciences industries and collaborates with organizations in the ophthalmology sector. The company was incorporated in 2023 and is based in Cambridge, Massachusetts.
Company website: www.citytx.com
CTY insider activity at a glance
FilingIQ tracks 9 insider transactions for CTY in filings since Oct 19, 2026. The most recent transaction is dated Oct 19, 2026.
Across the full history, 2 open-market purchases
and 0 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
How FilingIQ classifies each line, and the seven facts it shows on every open-market purchase and sale, are documented on the methodology page.
Latest CTY Form 4 filings
Most recent disclosures. Sign up to filter by transaction code, insider role or dollar value.
Other Healthcare tickers with recent insider activity
Most active insiders at CTY
By number of Form 4 lines in the last 180 days.
Frequently asked
- How many insider trades does FilingIQ track for CTY?
- FilingIQ tracks 9 Form 4 insider transactions for CTY (CITY THERAPEUTICS, INC.), covering filings from Oct 19, 2026 onwards. 9 of those are dated within the last 90 days.
- Are CTY insiders net buyers or net sellers?
- Across the full Form 4 history for CTY, 2 transactions (22%) were open-market purchases and 0 (0%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does CTY insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ links every filing to the insider's SEC CIK, marks plan trades, tax withholding, option exercises, gifts, derivatives and amendments, and shows each open-market purchase and sale with the same fixed facts. It does not rate the stock.
- What sector is CTY in?
- CITY THERAPEUTICS, INC. (CTY) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $1.08B.
Methodology & sources
Every CTY insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). How lines are classified and which facts FilingIQ adds is documented on the methodology page; the people behind it are on the team page. Not investment advice; see disclaimer.